3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Doxorubicin
33
pembrolizumab
16
Gemcitabine
15
eribulin
10
Irinotecan
10
olaratumab
9
Trabectedin
9
pazopanib
8
Docetaxel
8
Injections
7
Cyclophosphamide
7
Nivolumab
6
Fluorouracil
6
anlotinib
5
Temozolomide
5
Ipilimumab
5
Ifosfamide
5
Bevacizumab
5
tazemetostat
4
ridaforolimus
4
Drug Therapy
4
Cetuximab
4
Carboplatin
4
toripalimab
3
surufatinib
3
spartalizumab
3
ganitumab
3
entrectinib
3
conatumumab
3
belinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sarcoma
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts